Success Metrics

Clinical Success Rate
80.0%

Based on 8 completed trials

Completion Rate
80%(8/10)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
2(17%)

Phase Distribution

Ph not_applicable
3
25%
Ph phase_3
2
17%
Ph phase_1
2
17%
Ph phase_2
5
42%

Phase Distribution

2

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
2(16.7%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
2(16.7%)
N/ANon-phased studies
3(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(3)
Other(1)

Detailed Status

Completed8
Terminated2
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (16.7%)
Phase 25 (41.7%)
Phase 32 (16.7%)
N/A3 (25.0%)

Trials by Status

unknown18%
terminated217%
completed867%
withdrawn18%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT00004180Phase 2

Rosiglitazone in Treating Patients With Liposarcoma

Completed
NCT00616642Phase 2

Rosiglitazone in Treating Patients With Pituitary Tumors

Terminated
NCT00612066Phase 2

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Terminated
NCT00551564Phase 1

Study to Determine the Utility of Novel Technologies and Biomarkers to Measure Human Response to Rosiglitazone Maleate

Completed
NCT00116831Phase 3

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Completed
NCT00484419Phase 3

Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin

Completed
NCT00098852Phase 2

Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

Unknown
NCT00015691Not Applicable

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Completed
NCT00084578Not Applicable

Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the Bladder

Withdrawn
NCT00369174Phase 2

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

Completed
NCT00362726Phase 1

Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone

Completed
NCT00143624Not Applicable

Rosiglitazone (Avandia®) Treatment in HIV: Its Effect on Blood Vessels

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12